Technical Analysis for FENC - Fennec Pharmaceuticals Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 6.27 | 2.62% | 0.16 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Volume Surge | Other | 2.62% | |
| Lower Bollinger Band Walk | Weakness | 2.62% | |
| New 52 Week Low | Weakness | 2.62% | |
| Oversold Stochastic | Weakness | 2.62% | |
| Lower Bollinger Band Walk | Weakness | 1.95% | |
| Lower Bollinger Band Touch | Weakness | 1.95% | |
| Oversold Stochastic | Weakness | 1.95% | |
| New 52 Week Closing Low | Bearish | 4.15% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 8 hours ago |
| Up 3% | about 8 hours ago |
| Up 2% | about 8 hours ago |
| Up 1% | about 8 hours ago |
| Fell Below Lower Bollinger Band | 3 days ago |
Get a Trading Assistant
- Earnings date: 08/01/2024
Fennec Pharmaceuticals Inc. Description
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Oncology Blastoma Hearing Sarcoma Brain Tumor Cancer Therapeutics Childhood Neuroblastoma Neoplasms Localized Tumors Osteosarcoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.92 |
| 52 Week Low | 5.99 |
| Average Volume | 168,697 |
| 200-Day Moving Average | 8.77 |
| 50-Day Moving Average | 7.63 |
| 20-Day Moving Average | 6.61 |
| 10-Day Moving Average | 6.35 |
| Average True Range | 0.31 |
| RSI (14) | 35.48 |
| ADX | 29.08 |
| +DI | 13.40 |
| -DI | 25.62 |
| Chandelier Exit (Long, 3 ATRs) | 6.38 |
| Chandelier Exit (Short, 3 ATRs) | 6.92 |
| Upper Bollinger Bands | 7.27 |
| Lower Bollinger Band | 5.95 |
| Percent B (%b) | 0.24 |
| BandWidth | 20.09 |
| MACD Line | -0.41 |
| MACD Signal Line | -0.43 |
| MACD Histogram | 0.0202 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.57 | ||||
| Resistance 3 (R3) | 6.56 | 6.44 | 6.52 | ||
| Resistance 2 (R2) | 6.44 | 6.37 | 6.45 | 6.50 | |
| Resistance 1 (R1) | 6.36 | 6.32 | 6.40 | 6.37 | 6.49 |
| Pivot Point | 6.24 | 6.24 | 6.27 | 6.25 | 6.24 |
| Support 1 (S1) | 6.16 | 6.17 | 6.20 | 6.17 | 6.05 |
| Support 2 (S2) | 6.04 | 6.12 | 6.05 | 6.04 | |
| Support 3 (S3) | 5.96 | 6.04 | 6.02 | ||
| Support 4 (S4) | 5.97 |
